What Seaport Therapeutics’ Glyph platform reveals about the emerging science of gut lymphatic targeting
ARPA-H backs Seaport Therapeutics’ GlyphCele program targeting gut lymphatics in metabolic disease and pancreatic cancer. Read the analysis.
Pharma & Biotech